oral GlyT1 inhibitor
Ph. III candidate in schizophrenia
10 and 25 mg PO QD efficacy in CIAS improv.
J. Pharmacol. Exp. Ther.
Boehringer Ingelheim Pharma, Biberach an der Riss, DE
Iclepertin
Context. Iclepertin (BI 425809; Boehringer Ingelheim) is an oral glycine transporter-1 (GlyT1) inhibitor being developed for cognitive impairment associated with schizophrenia (CIAS). The ineffectiveness of currently available antipsychotic medications…